We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
2 Consumer Staples 1.53%
3 Industrials 0.67%
4 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGL icon
1
Agilon Health
AGL
$1.53B
$194M 4.88%
305,600
+5,800
+2% +$2.99M
HUM icon
2
Humana
HUM
$43.7B
$160M 4.04%
368,600
+19,600
+6% +$8.2M
PODD icon
3
Insulet
PODD
$11.5B
$128M 3.23%
481,700
+17,950
+4% +$4.41M
UNH icon
4
UnitedHealth
UNH
$376B
$122M 3.08%
240,000
– –
IDXX icon
5
Idexx Laboratories
IDXX
$44.1B
$120M 3.01%
218,750
+38,750
+22% +$20.4M
ARGX icon
6
argenx
ARGX
$53.4B
$110M 2.78%
350,000
+35,000
+11% +$10.2M
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.8B
$104M 2.61%
1,105,000
– –
ALGN icon
8
Align Technology
ALGN
$12.1B
$94.4M 2.38%
216,500
+16,500
+8% +$8.03M
HCA icon
9
HCA Healthcare
HCA
$87.2B
$94M 2.37%
375,000
-75,000
-17% -$18.8M
ISRG icon
10
Intuitive Surgical
ISRG
$127B
$90.1M 2.27%
298,500
-61,500
-17% -$18M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$78.5M 1.98%
746,000
– –
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.79B
$77.6M 1.95%
2,665,275
+18,650
+0.7% +$570K
EVH icon
13
Evolent Health
EVH
$348M
$76.9M 1.94%
2,380,000
+342,000
+17% +$8.95M
PCRX icon
14
Pacira BioSciences
PCRX
$1.04B
$76.3M 1.92%
1,000,000
– –
IMCR icon
15
Immunocore
IMCR
$1.72B
$76.3M 1.92%
2,552,034
+80,479
+3% +$2.03M
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$2.45B
$74.7M 1.88%
1,028,109
+144,188
+16% +$10M
EW icon
17
Edwards Lifesciences
EW
$49.6B
$70.2M 1.77%
596,500
+14,500
+2% +$1.63M
IRTC icon
18
iRhythm Holdings
IRTC
$3.85B
$68.7M 1.73%
436,000
+3,000
+0.7% +$385K
ACRS icon
19
Aclaris Therapeutics
ACRS
$726M
$66.6M 1.68%
3,865,034
+3,687
+0.1% +$50.3K
FRPT icon
20
Freshpet
FRPT
$2.93B
$60.8M 1.53%
592,500
+12,500
+2% +$1.18M
BPMC
21
DELISTED
Blueprint Medicines
BPMC
$60.5M 1.52%
947,715
+87,960
+10% +$6.31M
CERE
22
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$60.3M 1.52%
1,723,341
+74,906
+5% +$2.19M
BAX icon
23
Baxter International
BAX
$13.5B
$58.2M 1.47%
750,700
+16,897
+2% +$1.41M
SWAV
24
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$56.3M 1.42%
271,500
+49,000
+22% +$8.08M
KRTX
25
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$54.8M 1.38%
432,543
+5,700
+1% +$642K
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.